Intelligence / B2B SaaS / Acquisitions / Acura Pharmaceuticals, INC
Acura Pharmaceuticals, INC
6 Oct 2026: Completed an acquisition (SEC 8-K) · Pharma and biotech. Recorded in the SEC EDGAR full-text search.
- Filed
- 6 Oct 2026
- Role
- Completed an acquisition
- Sector
- Pharma and biotech
- Sic
- 2834
- Items
- 1.01, 2.01, 2.03, 9.01
- Summary
- Acura Forward-Looking Statements Statements in this Current Report constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and these forward-looking statements are made in reliance on the safe harbor provisions of Section 27A of the Securities Act of 1933, as ame
- Location
- Palatine, IL
- State
- Illinois
- Country
- United States
- SEC CIK
- 786947
- Reference
- 0001104659-26-114055
Integration means consolidating tools and vendors: the buyer re-platforms the target, and an acquired company's stack is reviewed by its new owner.
- Completed an acquisition leads with 189 of 292, then Sold assets or a business (82).
- 103 added in the 30 days to 19 Nov 2026.
Find the decision makers at Acura Pharmaceuticals, INC
AOS maps the buying committee, finds verified work emails and drafts outreach that cites this m&a signal, for your approval.
Across AOS Research
Other records for Acura Pharmaceuticals, INC in our registers.
More in Completed an acquisition
Acquisitions
Source: SEC EDGAR full-text search, data to 19 Nov 2026. Every Form 8-K reporting Item 2.01 (completion of an acquisition or disposition of assets) filed with the SEC in the last 90 days. The role (buyer, company acquired, seller) is read from the filing's own wording, which is quoted on each row. AOS shows what the public record says; it does not verify or endorse the company.